ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
06/25/2026
Back to search
Official data from USPTO
STAR-CRISPR
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
20
Latest update
06/25/2026
Trademark type
Combined
Nice classes
1, 5, 40, 42
Filing date
05/13/2025
Registration date
03/17/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/17/2026
Last transaction
06/25/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
5
Owner type
98
Owner location
BE
Examiner
EISNACH, MICHAEL PATRICK
Law office
L40
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Celyntra Therapeutics SA
Representatives
Jessica S. Sachs Harness, Dickey & Pierce, P.L.C.
Technical classification
Nice Classes
Class 1Class 5Class 40Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Reagents for research purposes; reagents used in science; reagents for scientific purposes; reagents for medical research; laboratory reagents for scientific use; chemical reagents for scientific purposes; reagents for scientific or medical research use; chemical reagents for use in genetic research; chemical reagents for use in biotechnologyother than for medical or veterinary use; specialized reagents for genome editing for scientificresearchlaboratory use; modified cellsin particular genetically modified ips (induced pluripotent stem) cells and differentiated cells derived therefromfor research or scientific purposes; cell culturescell culture systems and cryopreserved genetically modified ips cells for scientific and industrial research purposes; cell culturescryopreserved cells ips cells other than for medical or veterinary use; Biological preparations for use in cell culturesother than for medical or veterinary purposescell culture agents for use in the biotechnology industry and cell material for use in combination with human cellsincluding genetically modified ips or differentiated stem cells
Class 5
Medical diagnostic reagents; clinical medical reagents; clinical diagnostic reagents for medical use; reagents for use in medical genetic testing; cells for medical use; genetic identity tests comprised of reagents for medical purposes; specialized reagents for genome editing for medical and medical clinical use; modified cellsin particular genetically modified ips (induced pluripotent stem) cells and differentiated cells derived therefromfor medical or veterinary use; cell cultures and cell culture systemscryopreserved pluripotent stem cells for medical or veterinary use; genetically modified ips (induced pluripotent stem) cells for use in generating other cells for therapeutic purposes; cell cultures and cell culture systemscryopreserved genetically modified pluripotent stem cells for sub cultivation of cellsfor medical or veterinary use
Class 40
Custom manufacturing of iPS derived cellsiPS derived cell therapy and manufacturing processes for othersmanufacturing of the foregoing cells in GMP-based facilities; custom manufacture of therapeutic cellsmedicinescell therapies and gene edited cell therapies for othersincluding manufacturing in GMP-based facilities; custom manufacture of cellular therapiesincluding manufacturing in GMP-based facilities; manufacturing of cell lines being modified cells with specific genetic edits for use in generating other cells
Class 42
Structural and functional analysis of genomes; research and development in the field of microorganisms and cells; research in the field of gene editing technology; genetic research; gene therapy research; scientific research in the field of genetics and genetic engineering; research in the field of gene therapy; research in the field of genetic diseases; scientific research relating to genetics; biotechnology research; biotechnology testing; preparation of reports in the biotechnology field; research and testing of cell-based productsin particular therapeutic products; researchoptimization and testing of cell production processes; laboratory research in the field of biotechnology using genetically modified ips (induced pluripotent stem) cells and differentiated cells derived therefrom; scientific researchdesign and development of scientific cell culturecell therapy and gene edited cell therapy; scientific researchdesign and development of cell culturecell therapy and gene edited cell therapymanufacturing systems and manufacturing processes for others; platform as a service (PAAS) services featuring computer software platforms for custom manufacturing of cell-based products in the field of cell therapycell therapy development; providing temporary use of online non-downloadable computer software platform for the management of manufacturing of cell-based therapiesthe associated technologyprocessesdata analytics capabilities for process optimization and quality control
Publications
History of USPTO decisions and trademark events.
20 publications found
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/17/2026
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/17/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
03/17/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/27/2026
PUBO
PUBLISHED FOR OPPOSITION
01/27/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/21/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/06/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/05/2026
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/05/2026
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/05/2026
RFNT
REFUSAL PROCESSED BY IB
11/22/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
11/05/2025
RFRR
REFUSAL PROCESSED BY MPU
11/05/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
09/17/2025
CNRT
NON-FINAL ACTION WRITTEN
09/16/2025
DOCK
ASSIGNED TO EXAMINER
09/03/2025
MAFR
APPLICATION FILING RECEIPT MAILED
06/22/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/22/2025
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/19/2025
Continuous trademark protection
Get notified about every new filing that threatens STAR-CRISPR or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.